2022 World Conference on Lung Cancer (ePosters)-EP08.02-024. Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis

EP08.02-024. Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis

Back to course

Pdf Summary

Trials investigating the use of targeted therapy and immune checkpoint inhibitors (ICI) in the treatment of brain metastasis (BM) in non-small cell lung carcinoma (NSCLC) have seen increased interest. A study was conducted to analyze the trials registered on ClinicalTrials.gov database between January 2015 and December 2021 that included the keyword "brain metastasis." A total of 172 trials were identified, and 58 trials met the inclusion criteria.<br /><br />The majority of the trials (83%) focused on brain metastasis with lung primary, while the remaining 17% involved mixed primary tumors with lung cancer as a component. Most of the trials (77.6%) were phase II, followed by phase III (10.3%) and phase I & II combined (10.3%).<br /><br />The intervention models varied, with 74.1% of the trials being non-randomized and 25.9% being randomized. The trials were primarily initiated in Asia (46.6%), followed by North America (29.3%) and Europe (6.9%).<br /><br />There was a range of interventions being evaluated, with the most common being tyrosine kinase inhibitors (TKI) targeting EGFR or ALK (50%), ICI or TKI with chemotherapy (19%), and ICI alone (15.5%). Other interventions included vascular endothelial growth factor inhibitors (VEGFI) with or without chemotherapy, VEGFI with ICI, and cyclin-dependent kinase inhibitors.<br /><br />The trials had varying recruitment statuses, with 53.4% still recruiting, 17.2% not yet recruiting, and 8.6% terminated. The expected number of participants ranged from less than 50 to more than 100.<br /><br />The trial sponsorship was primarily by entities other than industry (55.1%), followed by industry-sponsored trials (15.5%) and a combination of industry and others (25.9%).<br /><br />The results of these trials will contribute to the understanding of the role of targeted therapy and ICI in the management of lung cancer patients with brain metastasis. The majority of the trials are phase II and are being conducted in Asia.

Asset Subtitle

Bindu Krishnappa Venugopal

Meta Tag

Speaker Bindu Krishnappa Venugopal

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

targeted therapy

immune checkpoint inhibitors

brain metastasis

non-small cell lung carcinoma

ClinicalTrials.gov

intervention models

tyrosine kinase inhibitors

chemotherapy

recruitment statuses

phase II trials